Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development

• Published in: Drug metabolism and pharmacokinetics Vol. 34; no. 1; pp. 3 - 13
• Main Authors: Glassman, Patrick M., Balthasar, Joseph P.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.02.2019
• Subjects: Animals; Antibodies, Monoclonal - chemistry; Antibodies, Monoclonal - pharmacokinetics; Drug development; Drug Development - methods; Drug Development - trends; Drug discovery; Drug Discovery - methods; Drug Discovery - trends; Humans; Models, Biological; Monoclonal antibodies; Pharmacokinetics; Physiologically-based pharmacokinetics; Tissue Distribution - drug effects; Tissue Distribution - physiology; Physiologically-based pharmacokinetics; Monoclonal antibodies; Drug discovery; Pharmacokinetics; Drug development
• ISSN: 1347-4367; 1880-0920; 1880-0920
• DOI: 10.1016/j.dmpk.2018.11.002

Over the past few decades, monoclonal antibodies (mAbs) have become one of the most important and fastest growing classes of therapeutic molecules, with applications in a wide variety of disease areas. As such, understanding of the determinants of mAb pharmacokinetic (PK) processes (absorption, distribution, metabolism, and elimination) is crucial in developing safe and efficacious therapeutics. In the present review, we discuss the use of physiologically-based pharmacokinetic (PBPK) models as an approach to characterize the in vivo behavior of mAbs, in the context of the key PK processes that should be considered in these models. Additionally, we discuss current and potential future applications of PBPK in the drug discovery and development timeline for mAbs, spanning from identification of potential target molecules to prediction of potential drug-drug interactions. Finally, we conclude with a discussion of currently available PBPK models for mAbs that could be implemented in the drug development process. [Display omitted]